Androgen News and Research

RSS

Androgen clock reveals how hormones shape aging and health

Scientists unveil the androgen clock, a precise epigenetic tool to measure long-term androgen exposure and its role in aging and health.

16 Jan 2025

RNA nanoparticles offer dual action against prostate tumors

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer."

10 Jan 2025

Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

3 Jan 2025

Assessing the impact of gozetotide in PSMA-positive prostate cancer

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177Lu)lutetium vipivotide tetraxetan ("Lutetium-177" for short) is an option.

20 Dec 2024

Dinuclear platinum(II) complexes could offer a more targeted approach to treating prostate cancer

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men.

16 Dec 2024

Study unveils key mechanism behind prostate cancer's uncontrolled growth

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

14 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

Spatial transcriptomics uncovers new treatment paths for triple-negative breast cancer

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative breast cancer (TNBC). The findings identify nine spatial archetypes and gene signatures linked to immunotherapy response and patient outcomes.

2 Dec 2024

EZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancer

An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers, according to a new study by scientists at Weill Cornell Medicine.

20 Nov 2024

Can probiotics improve insulin resistance in women with PCOS?

The review highlights the role of probiotics and synbiotics in enhancing insulin sensitivity and hormonal balance in PCOS, suggesting new avenues for treatment.

20 Nov 2024

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition.

30 Oct 2024

New research unveils mechanism behind deadly neuroendocrine prostate cancer

A leading scientist whose discoveries about prostate cancer led to lifesaving treatments is now shedding light on an emerging and deadlier form of the disease: neuroendocrine prostate cancer (NEPC).

28 Oct 2024

Gut microbiota composition linked to PCOS subtypes: regional and testosterone-based variations found

This analysis uncovers gut microbiota variations in PCOS, emphasizing the role of testosterone and regional factors in understanding the disorder's complexity.

22 Oct 2024

Researchers identify shared genetic variants between testosterone traits and PCOS

A genome-wide study reveals significant genetic overlap between polycystic ovary syndrome and testosterone-related traits, highlighting shared causal variants.

16 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

Insights into testosterone recovery after androgen deprivation therapy for prostate cancer

A study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center sheds light on testosterone recovery following androgen deprivation therapy (ADT) in men undergoing radiotherapy for prostate cancer, providing key insights for optimizing patient care.

26 Sep 2024